ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1820

Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity

Margaret Markiewicz1, Dayvia Russell2 and Jim Oates1, 1Medical University of South Carolina, Charleston, SC, Charleston, SC, 2.Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Biomarkers, Disease Activity, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the key complications of SLE with 10% of patients developing end-stage renal failure, and major risk for overall morbidity and mortality in SLE. The Klotho gene plays an important role in the process of aging, inflammation, and autoimmunity. Diminished levels of a-Klotho (Kl) were reported in age related diseases such as cancer, hypertension, and kidney disease. Significantly low a-Klotho levels were associated with an increased risk of progressive decline in renal function. The aim of our study was to evaluate the serum concentration of a-Klotho in patients with SLE only [Group I] ; SLE with hypertension (HTN)[Group II]; and SLE with lupus nephritis (LN) and HTN [Group III], and compare to that of healthy control and/or control with HTN to determine associations with disease and disease activity.

Methods: We used banked serum samples from patients and controls enrolled in a prospective longitudinal cohort study. Our study consisted of 20 paired serum samples from patients with SLE and/or LN and/or HTN (5 in each group) and 15 controls with or without HTN. SLE patients had serum collected during paired visits (first and second visit) with lower and higher disease activity determined through clinical and laboratory elements of the SLEDAI (SLE Disease Activity Index).The serum samples were analyzed through an enzyme-linked immunosorbent assay (ELISA) development system for the determination of human soluble a-Kl (R&D Systems).

Results: The serum concentration of Kl was 0.84 ± 0.599 ng/ml and 0.86 ± 0.449 ng/ml in SLE patients during inactive and active disease, respectively. Serum Kl averaged 0.82 ± 0.667 ng/ml in No HTN controls and 1.21 ± 1.252 ng/ml in HTN controls. Serum Kl negatively correlated with age among female SLE patients from all groups during active disease (r = – 0.524, p = 0.032). Interestingly, serum Kl concentration positively correlated with anti-dsDNA antibody levels in all females with active disease (r = 0.525, p = 0.046). Moreover, the serum Klotho concentration positively correlated with protein/creatinine ratio in females with active disease and LN (r = 0.974, p = 0.004). There was no association between Kl concentration and C3, C4 levels in SLE patients.

Conclusion: This is the first study measuring Kl levels in serum from the inactive and active stage of SLE with hypertension as a covariable. Klotho levels negatively correlated with age of SLE patients, which is similar to the diminished concentration of Kl seen with chronological aging. We initially postulated that Kl levels would decrease in SLE patients since serum Kl acts as an anti-inflammatory molecule, but did not see this in our study. Surprisingly, we found an association between Kl levels and the positivity of dsDNA titers and protein/creatinine ratio. The positive correlation between elevated levels of Kl and laboratory measures of disease activity may be a compensatory response to inflammation, while decreases with age may reflect accelerated immune senescence.


Disclosure: M. Markiewicz, None; D. Russell, None; J. Oates, None.

To cite this abstract in AMA style:

Markiewicz M, Russell D, Oates J. Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/serum-%ce%b1-klotho-is-decreased-in-older-systemic-lupus-erythematosus-patients-and-correlate-with-markers-of-disease-activity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-%ce%b1-klotho-is-decreased-in-older-systemic-lupus-erythematosus-patients-and-correlate-with-markers-of-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology